Abstract
Southern Africa is burdened with Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (M.tuberculosis) infections as well as conditions of iron (Fe) overload. Highly Active Antiretroviral Therapy (HAART) is used to treat HIV-infection, many drugs exist for the treatment of tuberculosis (new solutions are also being sought because of the existence of multi drug resistant strains of M.tuberculosis) and Fe chelators are commonly used to treat Fe overload. Chelators have also been shown to inhibit the multiplication of numerous microorganisms and hence there are publications suggesting a role for chelators like desferrioxamine (DFO) in the dual treatment of microorganism infection and excess iron. Excess iron fuels pathogen survival which in turn lowers host cell functionality (manifested as altered proliferation, cytokine secretion, etc); withholding iron (via a chelator) reverses the process, even more so when the cells are chelated for longer periods of time. Chelation with DFO is reviewed here by commenting on its immunomodulatory effect.
Keywords: Desferrioxamine, HIV, M.tuberculosis, iron, immunomodulatory, immune restoration
Current Pharmaceutical Design
Title: Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Volume: 15 Issue: 11
Author(s): A. Williams and D. Meyer
Affiliation:
Keywords: Desferrioxamine, HIV, M.tuberculosis, iron, immunomodulatory, immune restoration
Abstract: Southern Africa is burdened with Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (M.tuberculosis) infections as well as conditions of iron (Fe) overload. Highly Active Antiretroviral Therapy (HAART) is used to treat HIV-infection, many drugs exist for the treatment of tuberculosis (new solutions are also being sought because of the existence of multi drug resistant strains of M.tuberculosis) and Fe chelators are commonly used to treat Fe overload. Chelators have also been shown to inhibit the multiplication of numerous microorganisms and hence there are publications suggesting a role for chelators like desferrioxamine (DFO) in the dual treatment of microorganism infection and excess iron. Excess iron fuels pathogen survival which in turn lowers host cell functionality (manifested as altered proliferation, cytokine secretion, etc); withholding iron (via a chelator) reverses the process, even more so when the cells are chelated for longer periods of time. Chelation with DFO is reviewed here by commenting on its immunomodulatory effect.
Export Options
About this article
Cite this article as:
Williams A. and Meyer D., Desferrioxamine as Immunomodulatory Agent During Microorganism Infection, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846801
DOI https://dx.doi.org/10.2174/138161209787846801 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intervention of Toll-like Receptor-Mediated Human Innate Immunity and Inflammation by Synthetic Compounds and Naturally Occurring Products
Current Medicinal Chemistry Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Role of Polyphenols in Diet and Nutrition-An Updated Review
Current Nutrition & Food Science Systemic Vasculitis: An Epidemiological Perspective
Current Immunology Reviews (Discontinued) Matrix Metalloproteinases in Respiratory Diseases: From Pathogenesis to Potential Clinical Implications
Current Medicinal Chemistry Novel Thiazole Carboxylic Acid Derivatives Possessing a “Zinc Binding Feature” as Potential Human Glyoxalase-I Inhibitors
Letters in Drug Design & Discovery Autophagy and Crohns Disease: At the Crossroads of Infection, Inflammation, Immunity, and Cancer
Current Molecular Medicine ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines
Current Topics in Medicinal Chemistry A Dilemma of Functional Genomics: Count the Chickens or Study their Eggs ?
Current Genomics Meet Our Regional Editor
Current Microwave Chemistry Alternative Nucleophilic Residues in Intein Catalysis of Protein Splicing
Protein & Peptide Letters New Derivatives of BM212: A Class of Antimycobacterial Compounds Based on the Pyrrole Ring as a Scaffold
Mini-Reviews in Medicinal Chemistry Evaluation of Polyphenolic Profile and Antibacterial Activity of Pomegranate Juice in Combination with Rifampin (R) against MDR-TB Clinical Isolates
Current Pharmaceutical Biotechnology Recent Advances in the Synthesis of Biologically Relevant Selenium-containing 5-Membered Heterocycles
Current Organic Chemistry Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Current Pharmaceutical Design Presentation of Lipid Antigens by CD1 Glycoproteins
Current Pharmaceutical Design Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives
Letters in Drug Design & Discovery WITHDRAWN: Current Trends in the Detection of Biological Proteins and Immunological Assays using Graphene Quantum Dots
Current Analytical Chemistry Subject Index to Volume 1
Current Pharmacogenomics